1. Home
  2. OP vs SLXN Comparison

OP vs SLXN Comparison

Compare OP & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OP
  • SLXN
  • Stock Information
  • Founded
  • OP 2021
  • SLXN 2008
  • Country
  • OP Greece
  • SLXN Israel
  • Employees
  • OP N/A
  • SLXN N/A
  • Industry
  • OP
  • SLXN
  • Sector
  • OP
  • SLXN
  • Exchange
  • OP Nasdaq
  • SLXN NYSE
  • Market Cap
  • OP 8.5M
  • SLXN 5.0M
  • IPO Year
  • OP N/A
  • SLXN N/A
  • Fundamental
  • Price
  • OP $1.13
  • SLXN $1.35
  • Analyst Decision
  • OP
  • SLXN Strong Buy
  • Analyst Count
  • OP 0
  • SLXN 1
  • Target Price
  • OP N/A
  • SLXN $9.00
  • AVG Volume (30 Days)
  • OP 11.2K
  • SLXN 31.9M
  • Earning Date
  • OP 12-20-2024
  • SLXN 02-25-2025
  • Dividend Yield
  • OP N/A
  • SLXN N/A
  • EPS Growth
  • OP N/A
  • SLXN N/A
  • EPS
  • OP N/A
  • SLXN N/A
  • Revenue
  • OP $25,729,000.00
  • SLXN N/A
  • Revenue This Year
  • OP N/A
  • SLXN N/A
  • Revenue Next Year
  • OP N/A
  • SLXN N/A
  • P/E Ratio
  • OP N/A
  • SLXN N/A
  • Revenue Growth
  • OP 36.33
  • SLXN N/A
  • 52 Week Low
  • OP $1.02
  • SLXN $0.21
  • 52 Week High
  • OP $3.15
  • SLXN $13.56
  • Technical
  • Relative Strength Index (RSI)
  • OP 42.81
  • SLXN N/A
  • Support Level
  • OP $1.11
  • SLXN N/A
  • Resistance Level
  • OP $1.16
  • SLXN N/A
  • Average True Range (ATR)
  • OP 0.04
  • SLXN 0.00
  • MACD
  • OP 0.00
  • SLXN 0.00
  • Stochastic Oscillator
  • OP 18.52
  • SLXN 0.00

About OP OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

Share on Social Networks: